Inclusion Criteria:
- Male or female, without immunosuppressed organ transplant or immunocompromised and
who received a kidney transplant, or kidney-pancreas, or heart or lung or heart-lung,
or liver, or cells hematopoietic stem cells, and has given its consent
- Aged 18 to 75 years Children aged more than 12 months,
- PS <4
- Viral load determined EBV
- Life expectancy> 1 month
- Patient typed for HLA DP DQ DR ABC
- Patients with lymphoma in the immunosuppressed associated with EBV and failure,
partial response (<50%) or relapsed after treatment with monoclonal antibodies and /
or chemotherapy completed for at least three weeks. Patients with partial response
may have a PET scan to confirm the lack of response.
- Patient with a measurable mass to assess the response or bone marrow infiltration
and / or measurable blood and having frozen tumor material or having a repeat biopsy.
- Availability of a CTL matching at least two HLA or one HLA after validation experts
with tumor cells
- test de cytotoxicity negative
Exclusion Criteria:
- Patient Pregnant or lactating
- Concurrent infection with HIV
- EBV negative lymphomas
- If acute GVHD> grade II J-1 before injection (case grafts CSH)
- Treatment of molecules in pre-marketing authorization older than 21 days
- No matching at least two CTL HLA or non expert validation for the use of CTL with HLA
sharing a single tumor
- Test of cytotoxicity positive
- Lack of recognition of tumor cells when available